Running a MLYS wheel strategy lets you generate consistent premium income on Mineralys Therapeutics Inc while setting your own entry and exit prices on the underlying. Mineralys Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own MLYS, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best MLYS wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on MLYS, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable MLYS wheel from a losing one.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the MLYS wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your MLYS wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
